Statistics

Total Visits

Views
Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 1)65

Select a period of time:

Number of views in the range

Views
Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 1)20

Views

Views
June 20250
July 20254
August 20250
September 20253
October 20251
November 202512
December 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Mexico9
United States5
Brazil5
Canada1
 

Top cities views

Views
Mexico City6
Dallas3
São Paulo2
Halifax1
Macapá1
Paulo Frontin1
Registro1
Santa Clara1